Focused On-demand Library for Terminal nucleotidyltransferase 5C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q5VWP2

UPID:

TET5C_HUMAN

Alternative names:

Non-canonical poly(A) polymerase FAM46C

Alternative UPACC:

Q5VWP2; A3KMG2; Q8NE25; Q9NXK0

Background:

Terminal nucleotidyltransferase 5C, also known as Non-canonical poly(A) polymerase FAM46C, plays a crucial role in mRNA stability and gene expression by catalyzing the transfer of adenosine from ATP to mRNA poly(A) tails. This process not only enhances mRNA stability but also promotes gene expression, with a specific focus on mRNAs encoding endoplasmic reticulum-targeted proteins. Additionally, it has been observed to facilitate the replication of certain viruses, including the yellow fever virus, in response to type I interferon.

Therapeutic significance:

Understanding the role of Terminal nucleotidyltransferase 5C could open doors to potential therapeutic strategies, especially in the context of viral infections and the regulation of gene expression related to endoplasmic reticulum-targeted proteins.